Products

ChartWiz

This app lets users take a screenshot of any stock and crypto chart and it will give back analysis on it.

Website unidentifiedFinance / Crypto Wallets & Trading

Monthly visits
None yet
No traffic data yet
MRR
$8.42
30d received $02026-07-30
Entry price
$9.99/mo
Lower than 68% of peersNiche median $19/mo
Creators
deivcodes
@deivcodes· 512 followers
Launched
Unknown
No public launch record

Traffic & revenue

Last 12 months
Monthly visits

No traffic data yet.

Verified monthly revenueRevenue data stopped at 2026-10-11

Marketing moves

Launches, search & content, referrals, promotions

No launch, search, referral, or promotion moves recorded for this product yet.

Traffic sources

Traffic breakdown

No traffic channel or country breakdown data for this website yet.

Search

Domain authority —Domain registered Unknown

No search keyword data for this website yet.

Traffic data: Vaneform

Pricing

Public pricing: Free · In‑App Purchases · Pro Yearly $29.99 · Pro Monthly $9.99 · Weekly - 3 days free trial $3.99Raw source text; structured plans are extracted after website capture.

Pages & changes

Tracked since 2026-07-30

Key pages

Weekly snapshots

No page snapshots yet. Once followed, home and pricing pages are captured weekly.

Changes

No pricing, plan, or positioning changes detected since tracking started.

Questions & evidence

How much does ChartWiz cost?
The catalog records a monthly entry price of $9.99. Plan details and current billing terms are not yet available.
What is ChartWiz and what platforms does it support?
ChartWiz is catalogued under Crypto Wallets & Trading: This app lets users take a screenshot of any stock and crypto chart and it will give back analysis on it.. Supported platforms: Web.
What is ChartWiz's publicly disclosed revenue?
TrustMRR records verified MRR of $8.42 observed on 2026-07-30.Source

Related products in this category

Finance / Crypto Wallets & Trading

These products share a catalog category. Compare customer tasks, features and deployment requirements before treating them as alternatives.